This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at firstname.lastname@example.org or call 800-767-3771 ext. 9339.
Cancer treatment systems maker BSD Medical Corp. ( BSDM ) recently announced that it has inked an agreement with a third large U.S.-based distributor for selling and distributing the MicroThermX Microwave Ablation product lineup.
The new distributor is well-known for distributing specialty medical products in the domestic market with a long-standing record of several launches in thermal ablation.
BSD Medical is, thus, on the verge of setting up an exclusive domestic specialty distribution setup, which will provide coast-to-coast sales service for MicroThermX products. The company has selected distributors on criteria such as sales mix and concentration in interventional radiology.
BSD Medical has also recruited two regional sales managers in the western and central regions of the country in order to beef up both the distribution network and direct selling ability.
The MicroThermX Microwave Ablation System is a transportable, cutting-edge proprietary product, which includes a microwave generator, single-use antennas and a temperature monitoring mechanism. It is capable of generating significant level of power with one generator. Its usage helps approach larger and more uniform areas of ablation during a procedure.
The MicroThermX system leverages BSD Medical’s proprietary synchronous phased array technology to deliver precision-guided microwave energy to ablate soft tissues using a single-patient-use disposable antenna.
BSD Medical introduced the innovative MicroThermX system in the U.S. in December 2010. Subsequently, the Utah-based company successfully rolled out its first MicroThermX system in Europe in January 2011.
BSD Medical competes with established players like Boston Scientific ( BSX - Analyst Report ) and Angiodynamics ( ANGO - Analyst Report ) in the thermal ablation market. The global market potential for soft tissue ablation has been estimated to exceed $2.3 billion, offering a significant opportunity for BSD Medical.
Please login to Zacks.com or register to post a comment.